Recognizing False Biochemical Failure Calls After Radiation With or Without Neo-Adjuvant Androgen Deprivation for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 2, 2009, Pages 404-411

  Denham, James W ^a   Kumar, Mahesh ^b   Gleeson, Paul S ^a   Lamb, David S ^c   Joseph, David ^d   Atkinson, Chris ^e   Matthews, John ^f   Tai, Keen Hun ^g   Spry, Nigel A ^d   Christie, David ^h   Turner, Sandra ⁱ   Greer, Peter B ^j   D'Este, Catherine ^k   Steigler, Allison ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c WELLINGTON HOSPITAL   (New Zealand)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h Premion   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k UNIVERSITY OF NEWCASTLE   (Australia)

more..

Author keywords

Androgen deprivation; Biochemical failure; Prostate cancer; Radiation therapy

Indexed keywords

AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGIES; ANDROGEN DEPRIVATION; BIOCHEMICAL FAILURE; FAIL CRITERION; FALSE POSITIVES; GOSERELIN; PIECE WISE; POST TREATMENTS; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGENS; RADIATION ONCOLOGIES; RADIATION THERAPY; SEMINAL VESICLES;

ONCOLOGY; RADIOTHERAPY; TUMORS;

PEELING;

ANDROGEN; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REBOUND; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FALSE POSITIVE REACTIONS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 67349148564     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.047     Document Type: Article

References (15)

1. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 61 (2005) 1291-1298
2. Roach M.I., Hanks G., Thames H.J., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
3. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
4. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
5. Jani A.B., Al-Qamari A., Sapra B., et al. Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy. Clin Prostate Cancer 3 (2004) 43-48
6. Pickles T. The British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359
7. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
8. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
9. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
10. Kim Y.H., Choi B.I., Cho W.H., et al. Dynamic contrast-enhanced MR imaging of VX2 carcinomas after x-irradiation in rabbits. Invest Radiol 38 (2003) 539-549
11. Ciezki J.P., Reddy A., Garcia J., et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64 (2006) 512-517
12. Hanlon A.L., Moore D.F., and Hanks G.E. Modeling postradiation prostate specific antigen level kinetics. Cancer 83 (1998) 130-134
13. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
14. Alcantara P., Hanlon A., Buyyounouski M.K., et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109 (2007) 41-47
15. Horwitz E.M., Levy L.B., Thames H.D., et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation alone: A multiinstitutional pooled analysis. Canadian Med Assoc J 107 (2006) 1496-1502